TMDX rides OCS adoption and strong fourth-quarter results, but margin pressure raises questions for investors.

Earlier in 2026, TransMedics Group outlined its expansion beyond organ care devices into a vertically integrated National OCS ...

Innovations often (but not always) drive life-changing returns for the companies that engineer them and the people who get in on the ground floor. That's why investors should sometimes look toward ...

TransMedics remains the top dog in its industry and may have a widening moat. The founder-led company's shares have risen eightfold since 2019. TransMedics is consistently considered "overvalued," but ...

TransMedics delivered revenue and net income growth of 48% and 111% in its first-quarter earnings. The company continues to see streamlining efficiencies from its nascent logistical network. Solidly ...

In its latest quarter, TransMedics reported solid gains in revenue and saw net income nearly triple from year-ago levels. TransMedics increased its full-year 2025 sales outlook. Co-founder/CEO Waleed ...

It has been about a month since the last earnings report for TransMedics (TMDX). Shares have lost about 1.9% in that time frame, underperforming the S&P 500. But investors have to be wondering, will ...

ANDOVER, Mass., Feb. 9, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...

Shares of leading organ transplant technology company TransMedics (NASDAQ: TMDX) rose 15% as of noon ET on Thursday, according to data provided by S&P Global Market Intelligence. TransMedics reported ...

TransMedics is helping improve organ transplantation thanks to its innovative organ storage system. The company has posted strong financial results over the past few years, and the stock is soaring.